SMOKING MAY BE CONSIDERED AN ESTABLISHED RISK FACTOR FOR SPORADIC ALS
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Armon's1 review article on smoking and the risk of amyotrophic lateral sclerosis (ALS) referenced our cohort study based on the Swedish Construction Workers Cohort.2 The authors classified our study as Class IV evidence for a conclusion regarding the association between smoking and ALS. We do not agree with several of their criticisms.
First, the mean age of the Construction Workers Cohort was 35.5 years at the beginning of follow-up and 55.5 years at the end. Armon contends that this violated the validity of the study results. We do not believe that the population characteristics could influence the validity of a study when only internal comparisons were made.
Considering the generalizability of the results, we were not trying to assume that these results apply to other general populations given the specific features of construction workers. Although mainly young men, this cohort had a wide age range (i.e., age at entry to the cohort was 15–81 years). Age at enrollment is not relevant. However, age at ALS diagnosis could be relevant if smoking had differing effects on risk of ALS dependent on age. Regardless, the majority of our ALS cases were older. The mean age at ALS diagnosis was 64.4 years (range 31–85 years), with 15.6% at age <55 years, 15.6% 55–59 years, 18.1% 60–64 years, 18.8% 65–69 years, 14.4% 70–74 years, and 17.5% ≥75 years.
Secondly, the smoking information in our baseline questionnaire was obtained via the construction workers' personal interviews with a trained nurse. Presumably, this method is more reliable than self-report. Although the smoking status is not validated, as Armon mentions, we believe it is common in other large-scale follow-up studies.3,4 Furthermore, this was the method employed by another study cited by Armon, which they classified as Class I evidence.3
Disclosure: The authors report no …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis
Prof. Massimo Filippi and Dr. Paolo Preziosa
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Lifetime occupation, education, smoking, and risk of ALSN. A. Sutedja, J. H. Veldink, K. Fischer et al.Neurology, October 08, 2007 -
Article
Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosisElisa Longinetti, Daniela Mariosa, Henrik Larsson et al.Neurology, July 12, 2017 -
Null Hypothesis
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosisKjetil Bjornevik, Éilis J. O'Reilly, James D. Berry et al.Neurology, November 14, 2018 -
Resident and Fellow Section
Journal Club: Depression before and after diagnosis with amyotrophic lateral sclerosisJacquelyn J. Cragg, Ryan Seals, Neil Cashman et al.Neurology, November 21, 2016